News

The markers included morning cortisol levels, cytokines interleukin 1-β (IL-1β), as well as interleukin 2-R (IL-2R), blood pressure reactivity, and heart rate. These cytokines are known to be ...
The Swiss pharma group has agreed to buy Seattle-based biotech Good Therapeutics and its preclinical-stage PD-1-regulated IL-2 receptor agonist programme for $250 million upfront, with undisclosed ...